The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 480 participants.

Also called NCT06861088

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 480 participants (planned count) (from the registry)
Sponsor
Quercis Pharma AG (from the registry)
Registry
  • NCT NCT06861088
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06861088. Randomized; quadruple masking; primary purpose prevention. Start 2025-12-19 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Acronym
CATIQ P3
Condition
Venous Thromboembolism
Condition
Metastatic Pancreatic Cancer
Condition
Locally Advanced Pancreatic Adenocarcinoma
Intervention (Drug)
Kinisoquin™
Intervention (Drug)
Placebo
Lead sponsor
Quercis Pharma AG (class: industry)

Record details

Record id
cardio:ct-nct06861088
Content hash
cb8a860bc201c9179905d88b0624cfd7c86f274df6c4de3dd16d210774f485a2